Eyal C. Attar
2019
In 2019, Eyal C. Attar earned a total compensation of $1.2M as Chief Medical Officer at Aprea Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $121,825 |
|---|---|
| Option Awards | $766,208 |
| Salary | $301,250 |
| Total | $1,189,283 |
Attar received $766.2K in option awards, accounting for 64% of the total pay in 2019.
Attar also received $121.8K in non-equity incentive plan and $301.3K in salary.
Rankings
In 2019, Eyal C. Attar's compensation ranked 8,475th out of 13,971 executives tracked by ExecPay. In other words, Attar earned more than 39.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,475 out of 13,971 | 39th |
Division Manufacturing | 3,354 out of 5,701 | 41st |
Major group Chemicals And Allied Products | 1,270 out of 2,200 | 42nd |
Industry group Drugs | 1,080 out of 1,886 | 43rd |
Industry Pharmaceutical Preparations | 801 out of 1,398 | 43rd |
Source: SEC filing on April 29, 2020.
Attar's colleagues
We found two more compensation records of executives who worked with Eyal C. Attar at Aprea Therapeutics in 2019.
News
Aprea Therapeutics CEO Christian Schade's 2022 pay falls 58% to $1.4M
July 11, 2023
Aprea Therapeutics CEO Christian Schade's 2021 pay slips 17% to $3.2M
June 10, 2022
Aprea Therapeutics CEO Christian Schade's 2020 pay rises 6% to $3.9M
April 28, 2021
Aprea Therapeutics CEO Christian Schade's 2019 pay jumps 520% to $3.7M
April 29, 2020